SIGHINOLFI, LAURA
 Distribuzione geografica
Continente #
NA - Nord America 1.678
EU - Europa 730
AS - Asia 211
Continente sconosciuto - Info sul continente non disponibili 4
Totale 2.623
Nazione #
US - Stati Uniti d'America 1.677
PL - Polonia 555
CN - Cina 116
IT - Italia 89
VN - Vietnam 52
ID - Indonesia 31
GB - Regno Unito 28
DE - Germania 24
SE - Svezia 20
SG - Singapore 5
HK - Hong Kong 4
NL - Olanda 4
EU - Europa 3
IE - Irlanda 3
FR - Francia 2
UA - Ucraina 2
AP - ???statistics.table.value.countryCode.AP??? 1
CA - Canada 1
CZ - Repubblica Ceca 1
FI - Finlandia 1
IN - India 1
IQ - Iraq 1
RO - Romania 1
TR - Turchia 1
Totale 2.623
Città #
Warsaw 555
Fairfield 331
Ashburn 246
Woodbridge 145
Seattle 131
Houston 116
Wilmington 113
Cambridge 101
Chandler 95
Beijing 89
Dong Ket 52
Princeton 47
Ann Arbor 36
San Diego 34
Jakarta 31
Washington 22
Bremen 21
Ferrara 19
Santa Maria Di Sala 14
Shanghai 12
London 11
Bologna 9
Falls Church 9
Redwood City 9
Milan 5
Addison 4
Boardman 4
Chiswick 4
Hong Kong 4
Jacksonville 4
Norwalk 4
Rome 4
Chicago 3
Cordenons 3
Jinan 3
Mountain View 3
North Wales 3
Wuhan 3
Des Moines 2
Dublin 2
Haikou 2
Kilburn 2
Nanjing 2
New Bedfont 2
New York 2
Prescot 2
Teulada 2
Tianjin 2
Verolanuova 2
Augusta 1
Baghdad 1
Ballykisteen 1
Buffalo 1
Caerano di San Marco 1
Castel Guelfo di Bologna 1
Codognè 1
Florence 1
Gurgaon 1
Hounslow 1
Izmir 1
Jiaxing 1
Kansas City 1
Kunming 1
Ladispoli 1
Lappeenranta 1
Lentate Sul Seveso 1
Mesagne 1
Montreal 1
Munich 1
Olomouc 1
Roncegno 1
Santa Clara 1
Singapore 1
Somma Lombardo 1
Stockholm 1
Tappahannock 1
Zhengzhou 1
Totale 2.349
Nome #
Adipokines levels in HIV infected patients: lipocalin-2 and fatty acid binding protein-4 as possible markers of HIV and antiretroviral therapy-related adipose tissue inflammation 115
HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients 96
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 86
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV 81
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 77
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study 75
Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: data from the Icona cohort 73
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients 72
Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing 70
Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression 68
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort 68
Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy 68
Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study 67
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 64
Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort * 64
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 63
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 62
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 62
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 62
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 61
Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: Data from the Icona Foundation cohort 61
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 61
Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort 60
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 60
Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: The D: A: D study 59
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 59
Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D study 58
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 58
Disease progression in HIV Late Presenters: The role of HIV clinical indicator diseases prior to HIV diagnosis 58
A Comparison Between Different Anti-Retroviral Therapy Regimes on Soluble Inflammation Markers: a Pilot Study 56
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 55
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen 55
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 55
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 53
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 52
Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients 52
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 48
Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort 46
null 46
Switching from TDF to TAF or dual therapy (DT)-based regimens in HIV-infected individuals with viral load <= 50 copies/ml: does eGFR matter? 46
CD4+ T- cell count and CD4/CD8 ratio trend after HCV eradication in HCV/HIV-coinfected subjects treated with DAAs: an observational retrospective study over a 4 year period. 45
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 44
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 39
Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort 39
COVID-19 in eastern Emilia: an unusual epidemiology in Northern Italy 34
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 22
Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress? 11
Totale 2.786
Categoria #
all - tutte 15.716
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.716


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20195 0 0 0 0 0 0 0 0 0 0 0 5
2019/2020433 5 1 1 6 2 2 4 2 180 130 39 61
2020/20211.420 8 92 58 236 208 183 142 118 76 183 19 97
2021/2022345 41 19 2 5 15 44 21 28 16 40 12 102
2022/2023268 48 11 11 11 48 26 11 39 34 2 18 9
2023/2024294 14 27 30 15 47 93 11 7 5 3 2 40
Totale 2.786